Q-omics provides the consensus-scored HOXA5 profile across patient tissues and cancer cell-line models. HOXA5 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, HOXA5 is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, HOXA5 RNA expression shows 14,003 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, LUAD, and TGCT as cancer lineages where HOXA5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HOXA5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HOXA5 survival associations across molecular data types. HOXA5 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HOXA5 RNA expression–survival associations across cancer types. High HOXA5 expression shows unfavorable associations in UCEC, CESC, LGG, LAML and READ, but favorable associations in ACC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for HOXA5 RNA expression.
This table summarizes HOXA5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in LUSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for HOXA5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HOXA5 shows lower tumor expression in LUAD, LUSC, KICH, KIRC and BRCA and higher tumor expression in CHOL. The LUAD box plot shows higher HOXA5 RNA expression in normal versus tumor tissue (log2 FC = −2.034, t-test p < 0.001).
This table shows molecular features associated with HOXA5 in patient tissues and cancer cell lines. In patient samples, HOXA5 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, HOXA5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LARGE_INTESTINE.
